Pharmaceutical formulations: liposomes incorporating aromatic polyene antibiotics
US4999199A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 10, 1988 |
| Grant date | Mar 12, 1991 |
| Priority date | — |
| Expiry date | Nov 10, 2008 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/127
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention involves a pharmaceutical formulation comprising a liposome having a therapeutically effective concentration of an aromatic polyene macrolide antibiotic. The aromatic polyene macrolide antibiotic usable in the practice of the present invention is selected from the group consisting of candicidin, hamycin, aurefungin, ascosin, ayfattin, azacolutin, DJ400-B, trichomycin, levorin, heptamycin, candimycin or perimycin. The most preferred aromatic polyene macrolide antibiotic is candicidin. An important aspect of the present invention is a method for treating disseminated fungal infection in an animal comprising administering to an animal such as a human a pharmaceutical formulation comprising a liposome having a therapeutically effective amount of aromatic polyene macrolide antibiotic as described above. The preferred method of such administering is parenteral and the therapeutically effective amount is between about 1 mg/kg body weight and about 20 mg/kg body weight, more preferably between about 2.5 mg/kg body weight and about 6 mg/kg body weight. The parenteral administration is intravenous, intraarterial, subcutaneous, intramuscular, intralymphatic, intraperiton…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.